Why You Should Use Kinetic Modelling For Every Late Phase Development Project

In the pharmaceutical industry the use of kinetic modelling has found patchy uptake. Modelling is often seen by chemists as ‘something that engineers do’, or misunderstood as ‘too much effort – I’d rather run more experiments’. However, well-directed kinetic modelling can be a game-changing activity in helping to accelerate chemical development, achieve right first time scale-up, successfully transfer technology and implement new manufacturing modalities.

This webinar focused on the benefits offered by kinetic modelling, explaining how to:
• Gain value from kinetic modelling, especially minimising the amount of experiments and resources required for project delivery;
• Develop models that are ‘good enough’;
• Effectively combine kinetic modelling with Design of Experiments (DoE) studies;
• Use models as an aid to knowledge capture and tech transfer across teams and organisations;
• Use lab scale models during process scale-up and technology selection (e.g. flow processing).

The presenter, Dr Charlie Gordon, drew on his personal experience of using kinetic modelling to support the development of API manufacturing processes at Pfizer, and more recently as a consultant working for Britest and Scale-up Systems, supporting process development for a wide range of organisations of different sizes. This webinar was kindly sponsored by Scale-up Systems.